• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice.

作者信息

Wang Jinliang, Shuai Lei, Wang Chong, Liu Renqiang, He Xijun, Zhang Xianfeng, Sun Ziruo, Shan Dan, Ge Jinying, Wang Xijun, Hua Ronghong, Zhong Gongxun, Wen Zhiyuan, Bu Zhigao

机构信息

State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150069, China.

National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin, 150069, China.

出版信息

Protein Cell. 2020 Oct;11(10):776-782. doi: 10.1007/s13238-020-00767-x.

DOI:10.1007/s13238-020-00767-x
PMID:32749592
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7401472/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e397/7511497/7fb04c98c191/13238_2020_767_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e397/7511497/b931f0836715/13238_2020_767_Fig1a_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e397/7511497/7fb04c98c191/13238_2020_767_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e397/7511497/b931f0836715/13238_2020_767_Fig1a_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e397/7511497/7fb04c98c191/13238_2020_767_Fig2_HTML.jpg

相似文献

1
Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice.适应小鼠的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在BALB/c和C57BL/6J小鼠的上、下呼吸道中高效复制。
Protein Cell. 2020 Oct;11(10):776-782. doi: 10.1007/s13238-020-00767-x.
2
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.瑞德西韦在感染 SARS-CoV-2 的恒河猴中的临床获益。
Nature. 2020 Sep;585(7824):273-276. doi: 10.1038/s41586-020-2423-5. Epub 2020 Jun 9.
3
Uncertainty about the Efficacy of Remdesivir on COVID-19.瑞德西韦对COVID-19疗效的不确定性。
J Korean Med Sci. 2020 Jun 15;35(23):e221. doi: 10.3346/jkms.2020.35.e221.
4
Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection.评估小鼠和仓鼠对SARS-CoV-2感染的易感性。
Indian J Med Res. 2020 May;151(5):479-482. doi: 10.4103/ijmr.IJMR_2235_20.
5
3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.3C 样蛋白酶抑制剂可阻断冠状病毒在体外的复制，并改善 MERS-CoV 感染小鼠的存活率。
Sci Transl Med. 2020 Aug 19;12(557). doi: 10.1126/scitranslmed.abc5332. Epub 2020 Aug 3.
6
Audio Interview: New Data on Remdesivir in Covid-19.音频访谈：瑞德西韦治疗新冠病毒病的新数据
N Engl J Med. 2020 May 28;382(22):e94. doi: 10.1056/NEJMe2019975.
7
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
8
COVID-19: Rescue by transcriptional inhibition.新型冠状病毒肺炎：通过转录抑制进行挽救。
Sci Adv. 2020 Jul 1;6(27). doi: 10.1126/sciadv.abc6891. Print 2020 Jul.
9
Case report study of the first five COVID-19 patients treated with remdesivir in France.法国首例 5 例 COVID-19 患者接受瑞德西韦治疗的病例研究
Int J Infect Dis. 2020 Sep;98:290-293. doi: 10.1016/j.ijid.2020.06.093. Epub 2020 Jun 30.
10
Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters.金属药物雷尼替丁枸橼酸铋抑制 SARS-CoV-2 复制并缓解叙利亚仓鼠的病毒相关性肺炎。
Nat Microbiol. 2020 Nov;5(11):1439-1448. doi: 10.1038/s41564-020-00802-x. Epub 2020 Oct 7.

引用本文的文献

1
Exploring the biological mechanisms of severe COVID-19 in the elderly: Insights from an aged mouse model.探索老年人中重症新型冠状病毒肺炎的生物学机制：来自老年小鼠模型的见解
Virulence. 2025 Dec;16(1):2487671. doi: 10.1080/21505594.2025.2487671. Epub 2025 Apr 14.
2
Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs.在水貂、猫、蓝狐和貉中 SARS-CoV-2 mRNA 疫苗（SYS6006）的安全性和免疫原性。
Front Cell Infect Microbiol. 2024 Sep 19;14:1468775. doi: 10.3389/fcimb.2024.1468775. eCollection 2024.
3
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.

本文引用的文献

1
Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.生成一种广泛适用于 COVID-19 发病机制、疫苗接种和治疗的模型。
Cell. 2020 Aug 6;182(3):734-743.e5. doi: 10.1016/j.cell.2020.06.010. Epub 2020 Jun 10.
2
A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies.在小鼠中建立的 SARS-CoV-2 感染模型证明了中和抗体的保护作用。
Cell. 2020 Aug 6;182(3):744-753.e4. doi: 10.1016/j.cell.2020.06.011. Epub 2020 Jun 10.
3
Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2.
新发和再发传染病：全球趋势及预防和控制新策略。
Signal Transduct Target Ther. 2024 Sep 11;9(1):223. doi: 10.1038/s41392-024-01917-x.
4
The immunobiology of SARS-CoV-2 infection and vaccine responses: potential influences of cross-reactive memory responses and aging on efficacy and off-target effects.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染与疫苗反应的免疫生物学：交叉反应性记忆反应和衰老对疗效及脱靶效应的潜在影响
Front Immunol. 2024 Feb 26;15:1345499. doi: 10.3389/fimmu.2024.1345499. eCollection 2024.
5
SARS-CoV-2 immunity in animal models.动物模型中的 SARS-CoV-2 免疫。
Cell Mol Immunol. 2024 Feb;21(2):119-133. doi: 10.1038/s41423-023-01122-w. Epub 2024 Jan 18.
6
Current state-of-the-art and potential future therapeutic drugs against COVID-19.针对新型冠状病毒肺炎的当前最先进技术及潜在的未来治疗药物。
Front Cell Dev Biol. 2023 Aug 25;11:1238027. doi: 10.3389/fcell.2023.1238027. eCollection 2023.
7
Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants.目前流行的奥密克戎亚变种受体结合和更广泛种间受体识别的结构基础。
Nat Commun. 2023 Jul 21;14(1):4405. doi: 10.1038/s41467-023-39942-z.
8
Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.具有交叉中和活性的纳米抗体在轻度和重度 COVID-19 啮齿动物模型中提供显著的治疗效果。
Virol Sin. 2023 Oct;38(5):787-800. doi: 10.1016/j.virs.2023.07.003. Epub 2023 Jul 8.
9
Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro.新型冠状病毒3CL蛋白酶高效非共价抑制剂的研发
ACS Cent Sci. 2023 Jan 25;9(2):217-227. doi: 10.1021/acscentsci.2c01359. eCollection 2023 Feb 22.
10
Characterization of a Vesicular Stomatitis Virus-Vectored Recombinant Virus Bearing Spike Protein of SARS-CoV-2 Delta Variant.携带严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）德尔塔变异株刺突蛋白的水疱性口炎病毒载体重组病毒的特性分析
Microorganisms. 2023 Feb 8;11(2):431. doi: 10.3390/microorganisms11020431.
SARS-CoV-2 在表达人血管紧张素转化酶 2 的转基因小鼠中的发病机制。
Cell. 2020 Jul 9;182(1):50-58.e8. doi: 10.1016/j.cell.2020.05.027. Epub 2020 May 21.
4
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
5
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
6
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在人血管紧张素转换酶2（hACE2）转基因小鼠中的致病性。
Nature. 2020 Jul;583(7818):830-833. doi: 10.1038/s41586-020-2312-y. Epub 2020 May 7.
7
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
8
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
9
Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors.SARS-CoV nsp12 聚合酶与 nsp7 和 nsp8 辅助因子结合的结构。
Nat Commun. 2019 May 28;10(1):2342. doi: 10.1038/s41467-019-10280-3.